Filing Flows › 908 Devices (MASS) › Q1 2026 › vs Q1 2025
908 Devices (MASS) Q1 2026 vs Q1 2025 (year over year)
908 Devices's revenue rose $1.6M (+14%) from $11.8M in Q1 2025 to $13.4M in Q1 2026. The biggest changes: Device sales revenue +$1.9M (+26%); Recurring revenue −$282K (-7%).
908 Devices, Q1 2026: revenue $13.4M (+14% year over year), operating margin -96.3%, net loss $12.0M, operating cash flow $1.2M. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 8.7% | -128.9% | +137.6 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Device sales revenue | $9.4M | $7.4M | $1.9M | +26% |
| Recurring revenue | $4.0M | $4.3M | −$282K | -7% |
| Revenue | $13.4M | $11.8M | $1.6M | +14% |
| Other income, net | $929K | $54.6M | −$53.7M | -98% |
| Net loss | $12.0M | −$43.6M | $55.6M | — |
| Costs & expenses | $26.3M | $66.4M | −$40.1M | -60% |
| Operating costs | $26.3M | $22.8M | $3.5M | +15% |
| Cost of revenue | $6.5M | $6.2M | $263K | +4% |
| Research & development | $3.5M | $3.8M | −$358K | -9% |
| SG&A | $9.9M | $10.2M | −$325K | -3% |
| Other operating costs | $6.4M | $2.5M | $3.9M | +155% |
| Operating cash sources | $13.2M | −$58.6M | $71.8M | — |
| Depreciation & amortization | $1.1M | $1.3M | −$152K | -12% |
| Share-based compensation | $2.4M | $2.4M | $34K | +1% |
| Working capital & other | $9.6M | −$62.3M | $71.9M | — |
| Net loss absorbed | $12.0M | −$43.6M | $55.6M | — |
| Operating cash flow | $1.2M | −$15.0M | $16.2M | — |
| Free cash flow (OCF − capex) | $1.2M | −$15.2M | $16.3M | — |
| Capital expenditures | $40K | $159K | −$119K | -75% |
Questions
How much did 908 Devices's revenue grow year over year in Q1 2026?
908 Devices's revenue rose $1.6M (+14%) from $11.8M in Q1 2025 to $13.4M in Q1 2026.
What drove 908 Devices's revenue change in Q1 2026?
Device sales revenue +$1.9M (+26%); Recurring revenue −$282K (-7%).